Australia's most trusted
source of pharma news
Friday, 08 August 2025
Posted 5 August 2025 PM
Johnson & Johnson has coined a new term 'The 3rd Opinion' that seeks to elevate the patient voice, enhance shared decision-making and transform the journey of lung cancer patients across the Asia Pacific.
The 3rd Opinion is designed to spark a social movement that empowers patients. J&J said with significant scientific advancements and more lung cancer treatments becoming available, it is essential for patients to understand their options and actively engage in their care.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.